C Petruzziello
Overview
Explore the profile of C Petruzziello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Franceschi F, Saviano L, Petruzziello C, Gabrielli M, Santarelli L, Capaldi L, et al.
Eur Rev Med Pharmacol Sci
. 2016 Nov;
20(20):4401-4408.
PMID: 27831630
Diclofenac is the most widely prescribed non-steroidal anti-inflammatory drug worldwide. Data collected during the last 10 years reported a dose-duration dependent increasing of cardiovascular risk associated with the use of...
12.
Del Zompo F, Ojetti V, Feliciani D, Mangiola F, Petruzziello C, Tesori V, et al.
Eur Rev Med Pharmacol Sci
. 2016 Sep;
20(16):3452-6.
PMID: 27608906
Objective: Despite a growing interest toward the interplay between H. pylori and gastric microbiota, few data are available about this correlation. The aim of this study was to explore the...
13.
Franceschi F, Ojetti V, Gabrielli M, Petruzziello C, Tortora A, Gasbarrini G, et al.
Eur Rev Med Pharmacol Sci
. 2016 Feb;
20(2):297-300.
PMID: 26875899
Objective: Helicobater (H.) pylori eradication rates with standard first-line triple therapy have declined to unacceptable levels. To date, amoxicillin-resistant H. pylori strains have rarely been detected. Whether increasing the dosage...
14.
A bedside test for Clostridium Difficile infection: an Emergency Department use. Preliminary results
Marsiliani D, De Marco G, Petruzziello C, Merra G, Franceschi F, Ojetti V
Eur Rev Med Pharmacol Sci
. 2015 Sep;
19(17):3169-72.
PMID: 26400518
Objective: Clostridium Difficile (CD) infection is a severe cause of diarrhea in patients with prolonged hospitalization and/or previously treated with antibiotics. CD's A and B toxins are responsible for either...
15.
Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzziello C, et al.
Aliment Pharmacol Ther
. 2012 Apr;
35(12):1397-407.
PMID: 22519466
Background: Infliximab and adalimumab are highly effective in Crohn's Disease (CD). This is supported by clinical trials and open-label studies using either infliximab or adalimumab, thus not allowing a proper...
16.
Onali S, Calabrese E, Petruzziello C, Zorzi F, Sica G, Lolli E, et al.
J Crohns Colitis
. 2010 Dec;
4(3):319-28.
PMID: 21122521
Background And Aims: Ileocolonoscopy (IC) is the gold standard for assessing Crohn's Disease (CD) recurrence after ileo-colonic resection. In a prospective longitudinal study we compared findings related to CD recurrence...
17.
Biancone L, Petruzziello C, Calabrese E, Zorzi F, Naccarato P, Onali S, et al.
Gut
. 2009 Nov;
58(12):1703.
PMID: 19923350
No abstract available.
18.
Biancone L, Onali S, Calabrese E, Petruzziello C, Zorzi F, Condino G, et al.
Dig Liver Dis
. 2008 Jul;
40 Suppl 2:S265-70.
PMID: 18598999
Postoperative recurrence after ileo-colonic resection is a feature of Crohn's Disease (CD), almost 73% of patients show endoscopic recurrence at 1 year and 90% at 3 years. After surgical resection...
19.
Biancone L, Sica G, Calabrese E, Onali S, Petruzziello C, Pallone F
Am J Gastroenterol
. 2008 Mar;
103(3):809-11.
PMID: 18341511
No abstract available.
20.
Borgiani P, Perricone C, Ciccacci C, Romano S, Novelli G, Biancone L, et al.
Gastroenterology
. 2007 Sep;
133(3):1049-51.
PMID: 17854611
No abstract available.